Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab

Nandurkar, Harshal; Chaiwatanatorn, Kritika; Stamaratis, Georgia; Opeskin, Kenneth; Firkin, Frank

doi:10.3816/clm.2009.n.093

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The expression of PKCβ and p-AKT, two components of the PIK3/AKT signaling pathway, correlates with adverse outcome. 136,137 Moreover, expression of phosphotyrosine STAT3, enriched in ABC cases, has been associated with inferior outcomes in DLBCL patients. Notably, an 11-gene STAT3 activation signature has been shown to predict decreased OS, both in the entire DLBCL cohort as well as in the ABC subgroup as described by Huang et al 138 Adverse prognostic significance has also been attributed to the expression of indoleamine 2,3-dioxygenase (IDO) 139 and SKP2.…”

Section: Other Biomarkersmentioning

confidence: 99%

Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications

Papageorgiou

Thomopoulos

Katagas

et al. 2021

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment regimens over the last 20 years. In this context, prognostic biomarkers are of great importance in order to identify high-risk patients that might benefit from treatment intensification or the introduction of novel therapeutic agents. Herein, we review current knowledge on specific immunohistochemical or genetic biomarkers that might be useful in clinical practice. Gene-expression profiling is a tool of special consideration in this effort, as it has enriched our understanding of DLBCL biology and has allowed for the classification of DLBCL by cell-of-origin as well as by more elaborate molecular signatures based on distinct gene-expression profiles. These subgroups might outperform individual biomarkers in terms of prognostication; however, their use in clinical practice is still limited. Moreover, the underappreciated role of the tumor microenvironment in DLBCL prognosis is discussed in terms of prognostic gene-expression signatures, as well as in terms of individual biomarkers of prognostic significance. Finally, the efficacy of novel therapeutic agents for the treatment of DLBCL patients are discussed and an evidence-based therapeutic approach by specific genetic subgroup is suggested.

show abstract